Post-approval studies posted
This article was originally published in The Gray Sheet
Executive Summary
FDA lists more than 40 clinical studies on a 1Web site that went live April 6 tracking the ongoing status of post-approval medical device data collection ordered by the agency since Jan. 1, 2005 (2"The Gray Sheet" April 2, 2007, p. 26)...
You may also be interested in...
No More Secrets: CDRH Post-Approval Study Web Site Goes Live April 6
A public Web site tracking device companies' progress on FDA-required post-approval studies is scheduled to go live April 6
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.